Filtered By:
Management: Food and Drug Administration (FDA)
Therapy: Immunotherapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 401 results found since Jan 2013.
Breast cancer immunotherapy: a comprehensive review
Clin Exp Med. 2023 Sep 1. doi: 10.1007/s10238-023-01177-z. Online ahead of print.ABSTRACTCancer remains a major health problem despite numerous new medical interventions that have been introduced in recent years. One of the major choices for cancer therapy is so-called adoptive cell therapy (ACT). ACT can be performed using both innate immune cells, including dendritic cells (DCs), natural killer (NK) cells, and γδ T cells and acquired immune T cells. It has become possible to utilize these cells in both their native and modified states in clinical studies. Because of considerable success in cancer treatment, ACT now pla...
Source: Clinical Genitourinary Cancer - September 1, 2023 Category: Cancer & Oncology Authors: Samaneh Keshavarz Jack R Wall Somayeh Keshavarz Elham Vojoudi Reza Jafari-Shakib Source Type: research
Recombinant Antibody Fragments for Neurological Disorders: An Update
Curr Neuropharmacol. 2023 Aug 30. doi: 10.2174/1570159X21666230830142554. Online ahead of print.ABSTRACTRecombinant antibody fragments are promising alternatives to full-length immunoglobulins, creating big opportunities for the pharmaceutical industry. Nowadays, antibody fragments such as antigen-binding fragments (Fab), single-chain fragment variable (scFv), single-domain antibodies (sdAbs), and bispecific antibodies (bsAbs) are being evaluated as diagnostics or therapeutics in pre-clinical models and in clinical trials. Immunotherapy approaches, including passive transfer of protective antibodies, have shown therapeutic...
Source: Current Neuropharmacology - August 30, 2023 Category: Drugs & Pharmacology Authors: Karen Manoutcharian Goar Gevorkian Source Type: research
Current status of skin cancers with a focus on immunology and immunotherapy
Cancer Cell Int. 2023 Aug 21;23(1):174. doi: 10.1186/s12935-023-03012-7.ABSTRACTSkin cancer is one of the most widespread cancers, with a significant global health effect. UV-induced DNA damage in skin cells triggers them to grow and proliferate out of control, resulting in cancer development. Two common types of skin cancer include melanoma skin cancer (MSC) and non-melanoma skin cancer (NMSC). Melanoma is the most lethal form of skin cancer, and NMSC includes basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and other forms. The incidence of skin cancer is increasing in part owing to a demographic shift toward a...
Source: Cancer Control - August 22, 2023 Category: Cancer & Oncology Authors: Mahsa Khayyati Kohnehshahri Aila Sarkesh Leila Mohamed Khosroshahi Zanyar HajiEsmailPoor Ali Aghebati-Maleki Mehdi Yousefi Leili Aghebati-Maleki Source Type: research
Neoadjuvant immunotherapy in resectable non-small cell lung cancer
Clin Adv Hematol Oncol. 2023 Aug;(8):415-423.ABSTRACTLung cancer is the leading cause of cancer-related deaths worldwide and is associated with poor 5-year outcomes, even among the 20% to 25% of patients who present with operable disease. Cisplatin-based adjuvant chemotherapy has long been the standard of care for patients with resected non-small cell lung cancer (NSCLC). With the incorporation of immunotherapy, however, the treatment paradigm for NSCLC has changed dramatically. The introduction of immune checkpoint blockade has improved clinical outcomes in multiple phase 2 and 3 trials in both the neoadjuvant and adjuvan...
Source: Adv Data - August 2, 2023 Category: Epidemiology Authors: Sarah E Lochrin Patrick M Forde Source Type: research
Non-viral engineering of NK cells
Biotechnol Adv. 2023 Jul 14:108212. doi: 10.1016/j.biotechadv.2023.108212. Online ahead of print.ABSTRACTThe last decade has witnessed great progress in the field of adoptive cell therapies, with the authorization of Kymriah (tisagenlecleucel) in 2017 by the Food and Drug Administration (FDA) as a crucial stepstone. Since then, five more CAR-T therapies have been approved for the treatment of hematological malignancies. While a great step forward to treating several types of blood cancers, CAR-T cell therapies are still associated with severe side-effect such as Graft-versus-Host Disease (GvHD), cytokine release syndrome (...
Source: Biotechnology Advances - July 16, 2023 Category: Biotechnology Authors: Charlotte Hinnekens Stefaan C De Smedt Juan C Fraire Kevin Braeckmans Source Type: research
Development and application of oncolytic viruses as the nemesis of tumor cells
This article reviews the development, classification, and research progress of oncolytic viruses, as well as their mechanisms of action, therapeutic methods, and routes of administration.PMID:37440883 | PMC:PMC10335770 | DOI:10.3389/fmicb.2023.1188526
Source: Herpes - July 13, 2023 Category: Infectious Diseases Authors: Xiao Zhu Chenyang Fan Zhuolong Xiong Mingwei Chen Zesong Li Tao Tao Xiuqing Liu Source Type: research
Antibody-drug conjugates for urothelial carcinoma
Urol Oncol. 2023 Jul 5:S1078-1439(23)00219-3. doi: 10.1016/j.urolonc.2023.06.006. Online ahead of print.ABSTRACTThe standard of care for advanced urothelial carcinoma includes platinum chemotherapy and immunotherapy. Antibody-drug conjugates (ADCs), originally developed for hematologic malignancies, involve potent cytotoxic agents linked to antibodies that recognize tumor-specific antigens; this rational drug design allows for more on-target efficacy, while mitigating systemic toxicity. Herein, we review the emerging landscape of ADCs in urothelial carcinoma. The anti-Nectin-4 ADC enfortumab vedotin has demonstrated effica...
Source: Urologic Oncology - July 7, 2023 Category: Urology & Nephrology Authors: Joseph Thomas Michael Sun Ted Getz Benedict Ho Jones T Nauseef Scott T Tagawa Source Type: research
